Metraipolis › archive › dc_bfefae6bc670

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1 — Europe PMC PMID:41061701

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41061701
DOI: 10.1016/j.xcrm.2025.102407
License (as archived): solo-consultazione
Archived: 2026-11-09T13:12:07.294Z
SHA-256 of the archived text: 55c3c8dc2a0dc3cd6aafb2c771af27c1f61ac6517ecd1ba1168c83e521065a3d
Stable URL of this page: https://metraipolis.com/documento/dc_bfefae6bc670

How to cite

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1 — Europe PMC PMID:41061701 — Europe PMC (en), https://europepmc.org/article/MED/41061701 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bfefae6bc670 (Metraipolis archive dc_bfefae6bc670, sha256 55c3c8dc2a0dc3cd6aafb2c771af27c1f61ac6517ecd1ba1168c83e521065a3d)

BibTeX

@misc{dcbfefae6bc670,
  title = {CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1 — Europe PMC PMID:41061701},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41061701},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bfefae6bc670; sha256 55c3c8dc2a0dc3cd6aafb2c771af27c1f61ac6517ecd1ba1168c83e521065a3d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41061701. Agents can read the archived copy with the MCP tool read_document.